US Federal House Bill HB5032

US Federal 2025-2026 Regular Session

• Introduced: 8/22/25
• Refer: 8/22/25

Caption

Nitazene Control Act

Impact

If enacted, HB 5032 will implement a class-wide permanent scheduling of nitazenes under Schedule I of the Controlled Substances Act. This means that these substances will be classified as having a high potential for abuse and no accepted medical use. The bill aims to streamline enforcement measures and improve public health safety by preemptively controlling the proliferation of new nitazene analogs, thereby reducing the risks associated with these highly potent synthetic opioids. There is also a provision for the Attorney General to issue rules regarding the regulation of nitazenes, providing flexibility for enforcement.

Summary

House Bill 5032, known as the Nitazene Control Act, seeks to amend the Controlled Substances Act by permanently scheduling a class of synthetic opioids called nitazenes. These substances, first synthesized in the 1950s, have been found to exhibit extreme potency at the mu-opioid receptor, with some variants showing effectiveness greater than fentanyl. The legislation recognizes the urgent need to address the rising incidence of nitazenes in the illicit drug supply, which has been linked to severe overdose cases and fatalities throughout the United States.

Contention

While supporters of HB 5032 argue that it is a necessary step for protecting public health amidst a growing opioid crisis, concerns may arise regarding the implications for research. The bill allows researchers currently conducting studies involving nitazenes to continue without needing immediate registration, provided they meet certain requirements. This exemption is intended to balance the need for regulation with ongoing scientific exploration, yet critics may argue that further restrictions could hamper valuable research opportunities. Overall, the bill represents a significant action toward addressing a pressing health issue involving dangerous synthetic opioids.